ArticleScientific reports2025
Enhancing the solubility of celecoxib via lyophilized solid dispersions using computational and experimental approaches.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Biomimetic M2 exosome-based dual-drug nanoplatform for combined immunomodulation and bone protection in rheumatoid arthritis.Bioactive materials · 2026Article
- Biopharmaceutical Profiling of Herpetrione: A BCS II Properties and P-gp Substrate Guiding Nanoparticle Design.Pharmaceutics · 2026Article
- Supramolecular Cyclodextrin Nanofibers for Active Food Preservation: Current Trends and Future Perspectives.Foods (Basel, Switzerland) · 2026Review
- A cheminformatics and DFT exploration of a brominated sulfonamide with nonlinear optical response and preliminary in silico bioactivity assessment.Molecular diversity · 2026Article
- Inhibitory Effect ofInternational journal of nanomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Celecoxib (CLX), a selective COX-2 inhibitor and BCS Class II drug, is widely used for osteoarthritis and rheumatoid arthritis but having poor aqueous solubility (4.2 µg/mL) and limited dissolution, restricting its oral bioavailability. This study aimed to enhance CLX solubility and dissolution using integrated computational and experimental approaches. Simulated crystal morphology revealed a dominant (1 0 0) face, indicating a plate-like crystal habit that may hinder dissolution. Molecular dynamics simulations further identified hydroxypropyl β-cyclodextrin (HP-βCD) as the most compatible polymer, exhibiting the lowest interaction parameter (χ = - 5.86) and mixing energy (Emix = - 3.47 kcal/mol). Physical mixtures (PM1-PM4) were prepared at a 1:1 drug-to-polymer ratio and evaluated for solubility and recrystallization inhibition. PM1 (CLX-HP-βCD) showed the highest solubility (64.18 µg/mL) and longest induction time (140 s), indicating improved supersaturation stability. Lyophilized solid dispersions (SD1-SD4) were then developed and characterized using solubility studies, FTIR spectroscopy, microscopy, and in vitro dissolution testing. SD1 exhibited the greatest solubility enhancement (645 µg/mL), over 150-fold higher than pure CLX. FTIR and microscopy confirmed molecular dispersion and amorphization within the hydrophilic matrix. In vitro dissolution testing showed SD1 achieved 78.5% drug release in 3 h, with release kinetics best described by first-order (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.